At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Photo: Christophe Gateau/dpa (Photo by Christophe Gateau/picture alliance via Getty Images) ...

AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...

'The Big Money Show' discusses growing concerns over Anthropic's powerful AI model that can detect and exploit vulnerabilities, raising cybersecurity risks. Democrat Chedrick Greene’s win in Michigan ...

PARIS — RAS Luxury Skincare, the Indian farm-to-face brand, closed a 65 Crores, or $7.5 million, Series B funding round led by Dabur Ventures. Dabur Ventures is the venture arm of the largest ...

Every year, the NFL scouting combine allows for college football prospects to interview with NFL teams one-on-one for the first time. Franchises also use the time to get medical checkups for each ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people. These ...

Third-party model portfolios had $646 billion in assets under advisement as of March 31, 2025—an increase of 62% since Morningstar last surveyed for assets in June 2023, less than two years ago.

Forbes contributors publish independent expert analyses and insights. I write about the economics of AI. The AI boom has been defined by unprecedented innovation across nearly every sector. From ...

I am a proud, unapologetic progressive with a proven track record of action to protect our most vulnerable residents, create better education for our children, and forge pathways to affordable rent ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...